In Q3 2023, EcoR1 Capital held 37 positions worth $2.6B. They initiated 4 new positions and exited 16. Their largest holding was PRTA ($558.9M). Portfolio value shrank -26.4% versus the prior quarter.
Frequently asked questions
What stocks did EcoR1 Capital own in Q3 2023?
EcoR1 Capital held 37 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include PRTA, APLS, GLPGF, RVMD, ANAB. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was EcoR1 Capital's portfolio worth in Q3 2023?
EcoR1 Capital's tracked biotech portfolio was worth $2.6B across 37 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did EcoR1 Capital buy in Q3 2023?
EcoR1 Capital initiated 4 new positions in Q3 2023, including NMRA, MRSN, DCPH, GOSS. They also increased 5 existing positions.
What did EcoR1 Capital sell in Q3 2023?
EcoR1 Capital fully exited 16 positions in Q3 2023, including MGNX, KYMR, ITOS, ERAS, CGEM and 11 more. They also trimmed 3 existing positions.
Is EcoR1 Capital a biotech fund?
Growth-stage crossover fund investing in life sciences companies from late-stage private rounds through public equity. Named after the EcoR1 restriction enzyme, reflecting the firm's scientific roots. Focuses on platform technologies and novel therapeutic modalities.
Want AI analysis, insider signals, and catalyst overlays for EcoR1 Capital?
View latest EcoR1 Capital portfolio →